Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Ader

Showing results (31-40 of 169) with videos related to

Pageof 17
Sort By:
Antiviral Research|June 2, 2019
UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patientsThibault Labrunie, Sophie Ducastelle, Carine Domenech, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2017
Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface ModelingCharlotte Genestet, Florence Ader, Catherine Pichat, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 9, 2024
Encephalitis in HIV-negative immunodeficient patients: a prospective multicentre study, France, 2016 to 2019Sophie Landré, Florence Ader, Olivier Epaulard, et al.
BMC Public Health|October 15, 2025
Determinants of mpox vaccination uptake among MSM during the 2022 outbreak: a single-centre retrospective study at Lyon University Hospital, FranceYanis Merad, Matthieu Godinot, Dulce Alfaiate, et al.
International Journal of Antimicrobial Agents|June 7, 2011
Rifampicin-macrolide synergy against Legionella pneumophila serogroup 1 in human macrophages using a quantitative real-time PCR assayGhislaine Descours, Christophe Ginevra, Florence Ader, et al.
Bulletin Du Cancer|December 18, 2021
CAR-T cell: Toxicities issues: Mechanisms and clinical managementFlorent Wallet, Pierre Sesques, Perrine Devic, et al.
Infection and Immunity|March 31, 2010
Cooperation between multiple microbial pattern recognition systems is important for host protection against the intracellular pathogen Legionella pneumophilaKristina A Archer, Florence Ader, Koichi S Kobayashi, et al.
The Lancet. Infectious Diseases|June 1, 2022
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al.
Annals of Clinical Microbiology and Antimicrobials|February 28, 2025
In vitro activity of rifampicin, rifapentine and rifabutin in combination with their 25-deacetyl-metabolites against various Mycobacterium tuberculosis lineagesCharlotte Genestet, Chloé Bourg, Elisabeth Hodille, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Pageof 17

Showing results (31-40 of 169) with videos related to

Sort By:
Pageof 17
Antiviral Research|June 2, 2019
UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patientsThibault Labrunie, Sophie Ducastelle, Carine Domenech, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2017
Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface ModelingCharlotte Genestet, Florence Ader, Catherine Pichat, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 9, 2024
Encephalitis in HIV-negative immunodeficient patients: a prospective multicentre study, France, 2016 to 2019Sophie Landré, Florence Ader, Olivier Epaulard, et al.
BMC Public Health|October 15, 2025
Determinants of mpox vaccination uptake among MSM during the 2022 outbreak: a single-centre retrospective study at Lyon University Hospital, FranceYanis Merad, Matthieu Godinot, Dulce Alfaiate, et al.
International Journal of Antimicrobial Agents|June 7, 2011
Rifampicin-macrolide synergy against Legionella pneumophila serogroup 1 in human macrophages using a quantitative real-time PCR assayGhislaine Descours, Christophe Ginevra, Florence Ader, et al.
Bulletin Du Cancer|December 18, 2021
CAR-T cell: Toxicities issues: Mechanisms and clinical managementFlorent Wallet, Pierre Sesques, Perrine Devic, et al.
Infection and Immunity|March 31, 2010
Cooperation between multiple microbial pattern recognition systems is important for host protection against the intracellular pathogen Legionella pneumophilaKristina A Archer, Florence Ader, Koichi S Kobayashi, et al.
The Lancet. Infectious Diseases|June 1, 2022
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al.
Annals of Clinical Microbiology and Antimicrobials|February 28, 2025
In vitro activity of rifampicin, rifapentine and rifabutin in combination with their 25-deacetyl-metabolites against various Mycobacterium tuberculosis lineagesCharlotte Genestet, Chloé Bourg, Elisabeth Hodille, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Pageof 17